This webinar will be hosted live and available on-demand
Thursday, February 5th, 2026
11:00 AM – 12:30 PM ET
Regulator of G-protein signaling (RGS) proteins modulate GPCR signaling, making them potential therapeutic targets for several conditions, including cardiovascular disease and diabetes. However, identifying small-molecule inhibitors for RGS proteins has been challenging because many RGS family members lack well-defined binding pockets. Virtual modeling and screening approaches may accelerate drug discovery for RGS proteins and other difficult enzyme targets.
In this webinar, brought to you by BellBrook Labs, Robert Lowrey and David Siderovski present how AI-driven design and custom assay development can be integrated within an academic drug discovery program to develop inhibitors for the RGS14 protein.
Topics to be covered
- Why RGS proteins are challenging targets for small-molecule inhibitors
- How to apply virtual screening and AI to identify ligands for “undruggable” binding sites
- Designing custom biochemical assays for validating predicted RGS14 ligands
- How academic investigators and industry collaborators can integrate computational design and assay development for drug discovery
 |
Robert Lowery, PhD Chief Executive Officer BellBrook Labs |
 |
David Siderovski, PhD |
